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Abstract
Pythium insidiosum is an aquatic oomycete that causes invasive, progressive granulomatous
lesions of the skin in dogs, horses, and cats, and of the gastrointestinal tract in dogs. Quantitation of
anti-P. insidiosum IgG antibodies can be used in dogs to both confirm a suspected diagnosis and to
monitor response to therapy. Recently, an immunotherapeutic product (IP) has been marketed for the
treatment of pythiosis in dogs, horses, and people. The aim of this study was to evaluate the effect of
administration of this product on anti-P. insidiosum IgG concentrations in dogs. The IP was administered
to seven, healthy hound mixes on days zero, seven and 21. Serum was collected on days zero, seven,
14, 21, 28, 35, 42, 49, and 56. Anti-P. insidiosum antibody concentrations were measured using a
previously-described ELISA that utilizes a soluble mycelial-based antigen, with results reported as
percent positivity (PP) in comparison to a strong positive control serum. Prior to immunotherapy
administration, average PP was 7.45% +/- 3.02%. Following immunotherapy administration, there was
no significant change in anti-P. insidiosum antibody concentrations, with PP values in all dogs remaining
within the range expected for healthy dogs (3% - 15%) for the entire study period. In conclusion, the IP
did not produce a significant change in anti-P. insidiosum IgG concentrations when administered to
healthy dogs using the protocol suggested by the manufacturers. Further investigation will be required
to determine whether a similar effect is observed in naturally infected dogs.
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Chapter 1. Introduction and Literature Review
1.1 Pythium insidiosum
1.1.A

Brief history

Pythium insidiosum is an aquatic oomycete of the kingdom Stramenopila, Class oomycetes, Order
Pythiales and Family Pythiaceae [1]. It was historically called “bausette”, from “bausett”, the rainy
season, by Veterinary Surgeon James Kerr in India in 1829; as a condition affecting horses “which
appeared at the commencement of the rainy season and terminated as the dry season set in” [2]. The
first cases were described as small tumors around the lips, face and scrotum [2]. If not treated, the
tumors would “suppurate and become a bausette ulcer and from exposure to air become schirrous” [2].
It was thought that the smallest abrasion in susceptible horses was enough for the development and
these would “rapidly degenerate into bausette, if exposed to air” [2]. At this time, the etiology for this
condition was unknown. It wasn’t until 1879 in the East Indies that Smith reported that “bursattee”
originated in the subcutaneous tissue, referred to the tumors as “kunkur stones”, and suggested the
disease was caused by a mold-fungus [3]. In the United States in 1895, Dr. Pierre Fish wrote a historical
account comparing “bursattee” of the East Indies and “leeches”, a similar disease of horses and cattle in
Florida, as identical in nature [2].
Around the early 1900’s, de Haan and Hoogkamer described several cases of diseased horses in
Indonesia and named the disease as “hyphomycosis destruens” [4, 5]. In 1961, Bridges and Emmons
then described the etiologic agent as Hyphomyces destruens, a phycomycete (zygomycete) on the basis
of its morphology in equine tissue as well as its broad, branched sparsely septate to coenocytic, nonsporulating mycelium in cultures [6]. At this time, the agent was unable to sporulate in the media used
[6]. In 1974, Austwick and Copland reported the formation of biflagellate zoospores in isolates from
horses with “swamp cancer” from Papua, New Guinea [7]. These were grown on Sabouraud dextrose
agar and then transferred to an aqueous medium of rotten maize silage. From these results, they
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concluded that H. destruens was a phycomycete belonging to the Pythiaceae in the Peronosporales and
could be included in the genus Pythium Pringsheim [7].
It wasn’t until 1980 that Chandler, Kaplan and Ajello proposed changing the to the more appropriate
term “pythiosis” (also called: bursatii, Florida leeches, granular dermatitis, hyphomycosis destruens
equi, phycomycosis, phycomycotic granuloma and swamp cancer) [8]. In 1980, Ichitani and Amemiya
isolated a Pythium sp. from a Japanese case of equine pythiosis [9]. Based on the filamentous
zoosporangia, smooth oogonia, and aplerotic (oospores not filling the oogonium), smooth oospores that
it produced, it was considered part of the pre-existing species called Pythium gracile Schenk [9]. During
a two-year study of pythiosis in Costa Rican horses, numerous isolates of a Pythium species were studied
at the Centers for Disease and Control in Atlanta, Georgia [10]. A reliable and sensitive immunodiffusion
test for diagnosing pythiosis was then developed by Mendoza, Kaufman, and Standard [11]. Using the
immunodiffusion and fluorescent-antibody tests, Mendoza et al. demonstrated that isolates from the
horses in Costa Rica; Papua, New Guinea; United States; and Japan; isolates from humans in Thailand;
and isolates from dogs in the United States were identical [11]. Additional morphologic studies
demonstrated the formation of zoosporangia in water, which led the researchers to conclude that this
was a new species of Pythium [10]. De Cock, Mendoza, Padhye, Ajello and Kaufman finally described the
etiologic agent for pythiosis as Pythium insidiosum [10].
1.1.B

Organism

The organism’s cell walls lack chitin and ergosterol but contain cellulose and β-glucan. In this
manner, P. insidiosum is more closely related to algae than it is to fungi [1]. P. insidiosum incorporates
sterols from the environment rather than producing them itself [1]. The sexual reproductive structures
are oogonia and antheridia, and the asexual reproductive structures are zoospores [10]. It undergoes
asexual reproduction, which is characterized by the production of “motile, reniform, biflagellate
zoospores that develop by progressive cleavage within a vesicle that forms at the end of a discharge
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tube produced by a zoosporangium” [10]. Its sexual reproductive structures are “characterized by
intercalary, smooth, and subglobose oogonia; diclinous antheridia that produce a rigid fertilization tube
from their tip; and oospores that are aplerotic and often pressed to one side of the oogonium” [10].
Due to the difficulties associated with induction of sporulation under laboratory conditions, the
organism has been classified as a zygomycete or “phycomycete” [1]. P. insidiosum grows well at 37°C
and produces motile biflagellate zoospores in water culture [1]. Since P. insidiosum isolates rarely
produce sexual reproductive structures in the lab, presence and description of the hyphae, which are
broad (mean of 4 µm; range 2-7 µm), rarely septate, and occasionally branching at right angles [1] help
the clinician with diagnosis.
P. insidiosum is found in subtropical to tropical aquatic environments in Asia, Australia, and parts of
Central and South America [12]. Most infections with P. insidiosum (pythiosis) in the United States are
seen during the summer and fall along the Gulf of Mexico [12]. Areas with stagnant water (especially
associated with flooding or hurricanes) are frequently associated with outbreaks of pythiosis.
1.1.C

Pathogenesis

The infectious form of P. insidiosum is the motile biflagellate zoospore which usually infects by
encysting in damaged skin or GI mucosa [1]. The zoospore has an anterior tinsel flagellum and a
posterior whiplash flagellum [10]. These allow the zoospore to locate, move toward, and encyst on
specific host tissues or other substrates [1]. Zoospores then use chemotaxis, electrotaxis, and autoaggregation (i.e., dense accumulations of zoospores attract others, thereby increasing inoculum for
infection) [1]. Once the zoospores contact an open wound, they “form a germ tube that mechanically
penetrates tissues” [13]. Once into the tissues, P. insidiosum’s hyphae produce exoantigens that trigger
an immune response with eosinophils, mast cells and sometimes IgE [13]. It has been proposed that the
constant production of this exoantigen causes the host’s immune response to develop a Th2
immunologic polarization [13]. However, no work to support this assertion has been performed. The
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“overwhelming number of degranulated eosinophils (Splendore-Hoeppli phenomenon) and mast cells
around the hyphae of P. insidiosum are primarily responsible for the extensive and rapid tissue damage
encountered during pythiosis” [13]. Splendore-Hoeppli reaction is thought to be a localized
immunological response to an antigen-antibody precipitate related to fungi, parasites, bacteria or inert
materials [14]. The formation of the Splendore-Hoeppli reaction may inhibit phagocytosis and
intracellular killing of the agent leading to persistence of infection [14]. This hypothesis is supported by
the fact that viable hyphae of P. insidiosum have been found only inside the eosinophilic reaction or
inside kunkers in equine infections, suggesting that P. insidiosum might use the Splendore-Hoeppli
phenomenon and kunkers for survival [13].
1.1.D

Species affected and clinical syndromes

Species commonly affected by P. insidiosum include dogs, humans and horses, although there have
also been cases reported in other animals such as cattle, sheep, birds, as well as animals held in captivity
[15]. Affected dogs and horses are generally immunocompetent and otherwise healthy overall [1, 13,
15]. In contrast, affected humans often suffer from some preexisting systemic illness, such as βthalassemia [16].
Healthy dogs with access to water in the tropical and subtropical regions are commonly affected
with P. insidiosum [12]. Usually infections appear to occur through damage of the skin, where the
organism gains access while the animal is in flooded areas or when swimming [12]. The incidence is
highest in young, male, large breed dogs, and lesions are most commonly on the limbs, perineum, tail,
and head [17]. Pythiosis typically takes one of two clinical forms in the dog: cutaneous and
gastrointestinal [1, 13, 15]. Cutaneous and gastrointestinal pythiosis seldom occur in the same patient
[1].
Cutaneous lesions typically appear as non-healing wounds or invasive, progressively enlarging,
pyogranulomatous masses that contain ulcerated nodules and draining tracts [17]. Regional
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lymphadenopathy is often present and may reflect extension of infection rather than just reactive
inflammation [1].
Gastrointestinal pythiosis is characterized by severe transmural thickening of the stomach, small
intestine, colon, rectum, or, rarely, the esophagus [18]. Mesenteric lymphadenopathy is common, and
the gastric outflow area and ileocecal junction are the most frequently infected portions [1]. It is not
uncommon to find two or more segmental lesions in the same patient [1]. Most commonly, the
submucosa is affected with variable mucosal ulceration and occasional extension through the serosal
surfaces, which can result in adhesion formation and peritonitis [1]. Treatment of gastrointestinal
pythiosis is challenging, as no treatment modality is 100% effective for all cases presented, and the
prognosis is poor to grave [19]. It is best treated with wide (i.e., 3 to 4 cm margins) surgical excision,
followed by prolonged courses (> 4 months) of antifungal chemotherapy [19]. Reports of survival have
been documented in one case treated with partial gastrectomy, as well as another dog treated medically
with a combination of itraconazole, terbinafine, and mefenoxam [19].
In horses, pythiosis can also be referred to as swamp cancer, leeches or summer sores [20]. The two
most common presentations are cutaneous and subcutaneous, although gastrointestinal involvement
has been described [20]. No predisposing factors (age, sex, and breed) have been described; however,
immunocompetent horses exposed to warm, fresh water in swampy areas are at an increased risk of
contracting the infection [20]. Transmission is through colonization of traumatic lesions by zoospore
and/or hyphae of P. insidiosum [21] or by ingestion of P. insidiosum-contaminated water [22]. Lesions
typically occur on the limbs and ventral abdomen and are often intensely pruritic. Patients may
demonstrate mild to marked lymphadenopathy [20]. Lesions may demonstrate gritty, often branching
yellow concretions (kunkers). Kunkers in horses are formed by degranulation of eosinophils over the
invading hyphae of P. insidiosum [21]. In chronic infections (> 4 weeks), the infection may spread to the
underlying bone and cause lameness [21]. The only place where the hyphae can be found in these
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chronic infections is within the kunkers [20]. Though most cases of pythiosis in horses are cutaneous
and subcutaneous, intestinal infections have also been reported [21, 22]. Intestinal infections consist of
stenotic fibrous and disseminated gastrointestinal lesions [21]. Cases with intestinal pythiosis are
associated with clinical signs of colic that can be associated with partial luminal obstruction [22].
The development of pythiosis in humans is rare in the United States, but is commonly seen in
Southeast Asia. There are 4 types of pythiosis in humans: vascular (59%), ocular (33%),
cutaneous/subcutaneous (5%) and miscellaneous forms (3%) [23]. In contrast to horses and dogs (which
are typically otherwise healthy), humans with pythiosis are often immunologically compromised [23].
These patients suffer from diseases such as aplastic anemia, β-thalassemia, α-thalassemia, paroxsysmal
nocturnal hemoglobinuria and Hemoglobin E disease, all caused by mutations in the HBB gene [16, 23,
24]. Patients typically have histories of exposures to rice fields or access to flooded or swampy areas for
swimming. Clinical signs depend on the type of infection, but most vascular pythiosis patients present
with chronic arterial insufficiency syndrome of the lower extremities, which varies from intermittent
claudication to gangrenous ulceration [23].
1.1.E

Methods of diagnosis

1.1.E.1 Histology and immunohistochemistry
The diagnosis of infection with P. insidiosum can be challenging. Histologic examination of
biopsy material may demonstrate the presence of broad, irregularly branching hyphae. Although
hyphae are difficult to visualize with H&E-stained sections, they may appear as hyphal-shaped “clear
spaces” surrounded by a narrow band of eosinophilic material [1]. Hyphae are visualized easily in
sections stained with Gomori’s methenamine silver (GMS), but not with periodic acid-Schiff (PAS) [1].
Unfortunately, histologic examination alone cannot reliably distinguish the hyphae associated with P.
insidiosum from those of some species of true fungi (e.g., Basidiobolus) [25].
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Immunohistochemical techniques based on polyclonal antibodies have been developed for P.
insidiosum by Brown [26] and Newton [27] and had been used as confirmatory tests [1]. However, these
tests have been found to be cross-reactive with other species such as Conidiobolus, Basiodiobolus and
Lagenidium hyphae [1]. Therefore, specificity of this antibody for the immunohistochemical diagnosis of
pythiosis is questionable [1].
An additional factor complicating the diagnosis of gastrointestinal pythiosis is the depth of the
infection. In these cases, granulomatous inflammation is often centered on the submucosal and
muscular layers rather than the mucosa and lamina propria [1]. For this reason, the diagnosis can be
missed on endoscopic biopsies that fail to reach deeper tissues [1]. Pythiosis should be considered a
differential diagnosis when endoscopic biopsies reveal eosinophilic or pyogranulomatous inflammation
without identification of an etiologic agent [1].
1.1.E.2 Culture
Pythium may be cultured from tissue, but the organism is somewhat susceptible to temperature
extremes and may be killed by prolonged refrigeration, making transport inconvenient [25]. In addition,
the use of inappropriate media and technique during culture can also lead to false negative results [25].
In addition to this, induction of sporulation, which can facilitate proper identification, can be difficult in a
laboratory setting [25].
1.1.E.3 PCR
Although molecular diagnostics can identify P. insidiosum, these methods are not readily
available to most practitioners in a clinical setting [25]. Nested polymerase chain reaction (PCR) based
assays for identification of P. insidiosum can be applied to DNA extracted from cultured isolates or from
appropriately preserved infected tissue samples [28]. When using these tissues, Grooters found that
freezing samples at -70° C, or storing them at ambient temperature in 95% ethanol adequately
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preserved DNA for subsequent amplification [1]. Due to the sensitivity of this assay, archival samples
may be also tested [1].
1.1.E.4 ELISA
Perhaps the most practical method of diagnosis of P. insidiosum, especially for the dog, is by the
demonstration of anti-P. insidiosum IgG antibodies using an enzyme-linked immunosorbent assay
(ELISA) [25]. An ELISA utilizes an enzyme conjugated to an anti-canine IgG antibody [29]. This conjugate
reacts with a colorless substrate to generate a colored reaction product, with the amount of color
indicating quantity of the product [29].
This method also has the advantage of permitting evaluation of the course of treatment in dogs, as
antibody levels generally rise and fall in conjunction with the host’s pathogen burden [18, 30]. In
general, concentrations increase with the progression or worsening of infection [19, 30].
The IgG ELISA used in this study has been previously described and evaluated in dogs and has a
100% specificity and sensitivity for pythiosis [25]. Results of the assay are expressed as percent
positivity (PP) in comparison with a strong positive control sample, with values > 40% positivity having
been shown to be 100% sensitive and specific for canine pythiosis and values in healthy dogs ranging
from 3-15% [25].
1.1.E.5 Other assays
Agar gel immunodiffusion (AGID) detects precipitating antibodies in the serum of most equine
and human patients with active pythiosis, but often is negative in affected dogs [1]. Western
immunoblot analysis has been used successfully to demonstrate the ability of sera from Pythiuminfected horses and dogs to recognize antigens of P. insidiosum, and it has the added advantage of high
specificity and sensitivity [1]. However, this immunoblot technique is time and labor intensive
compared to other techniques (e.g., ELISA) for the detection of antibodies in the serum [1].
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1.1.F

Prognosis and treatment

1.1.F.1 Traditional treatment
Treatment of pythiosis is challenging and consists of a multi-modal approach by wide-margin
surgical excision (when possible) and antifungal chemotherapy for prolonged periods of time [25, 30,
31]. Although P. insidiosum resembles fungi in culture and in tissue, it is not a true fungus and contains
neither ergosterol nor chitin in its cell walls [10]. As most antifungal drugs primarily target these
molecules, medical management alone generally has limited efficacy against P. insidiosum. In addition,
infections with the organism are typically very locally invasive, and often extend microscopically far
further than their clinical appearance would suggest. For this reason, radical excision or amputation of
the affected area is usually recommended. Unfortunately, diagnosis of pythiosis is often delayed as the
lesions typically seen with P. insidiosum infections may easily be mistaken for other conditions, such as
acral lick granulomas in dogs or “proud flesh” in horses. Thus, lesions may become very large and/or
extensive by the time a definitive diagnosis is made.
A dramatic decrease in IgG concentrations has been seen in dogs and cats following successful
surgical resection [1]. In contrast, antibody levels remain high in animals that develop recurrence
following surgical treatment [1]. In this case, it is recommended to continue medical therapy with reevaluation of the ELISA every 2-3 months [1]. Efficacy of treatment depends on location of the lesion
(thoracic vs limb), type of infection (vascular, cutaneous, or visceral), chronicity of the infection and the
individual patient’s immune response (immune-compromised or immune-competent). It has been
reported that long-term infections of more than 4 weeks have a worse prognosis than early detected
and treated infections [32].
1.1.F.2 Immunotherapeutic Product development as newer form of treatment
Recently, an immunotherapeutic product (IP) has been developed and marketed for use in the
treatment of pythiosis in horses, dogs and humans. The first IP for P. insidiosum was designed for
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horses. This product used a whole cell, killed, sonicated hyphal preparation of P. insidiosum and was
developed by Miller in the 1980’s [33]. A positive response was observed within seven to 14 days after
the first injection. However, swelling and sterile abscesses were frequently observed at the injection
site [34]. A subsequent improved formulation was designed to have enhanced immunotherapeutic
properties due to the addition of both secreted exoantigens as well as cytoplasmic antigens of P.
insidiosum [13]. In studies conducted by Mendoza et al. the new IP formulation, containing an equal
mixture of exoantigens plus cytoplasmic immunogens, has been reported to produce clinical cure of 72%
of the 26 injected horses, including chronic cases [13]. These findings suggested that the addition of
cytoplasmic antigens dramatically increased the IP’s curative properties [13].
There have been several reports in which the IP has been administered to dogs. While some of
these cases appear to have been successfully treated, the efficacy in canines seems to be less than that
reported in horses [12, 19]. The majority of these cases have received both traditional therapy (medical
or surgical) and the IP. Oldenhoff reported administration of the IP to a 4-year old German shepherd;
however, new lesions formed despite the initiation of the IP. Traditional medical management
(itraconazole and terbinafine) was added but the patient was later lost to follow-up [18]. Pereira
reported a 2.5-year old Beagle in which intestinal pythiosis caused luminal obstruction, requiring
exploratory laparotomy and biopsy. After surgery, the beagle was administered the IP in addition to
terbinafine and itraconazole. The remaining affected area was completely resolved by 60 days [15].
Hensel reported a 4-year old Labrador retriever with a lesion on the carpus. After partial surgical
excision, the retriever was administered the IP twice. The lesion had resolved by one year post
treatment [17]. Dykstra published a report of 2 dogs which were treated using a combination of
immunotherapy and medical management [35]. Neither animal responded to treatment and both were
euthanized shortly after presentation. Schmiedt reported a 1.5-year mixed-breed dog with 1-month
history of vomiting and anorexia, later diagnosed as intestinal P. insidiosum [19]. This patient was
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treated by a subtotal colectomy, followed by administration of the IP. The patient achieved significant
improvement by two months post-surgery [19]. In contrast, Mendoza reported two dogs which
achieved a cure following administration of the IP alone, after prior medical management had failed
[13].
1.1.F.3 Prognosis
Long-term prognosis in dogs infected with P. insidiosum depends on chronicity of infection, location
of lesion and treatment modalities used. In general, the prognosis of chronic infections (> 2 months) is
poor [13]. Medical management alone is generally thought to have limited efficacy, as P. insidiosum
does not contain most of the structures targeted by traditional antifungal medications. For this reason,
surgical excision is currently considered the mainstay of effective therapy, especially in the dog. It is
suspected that only an amputation or radical surgical excision with wide-surgical margins can truly stop
the spreading of the infection through the subcutaneous planes. Unfortunately, radical excision is
difficult in cases where the lesions include the stomach and small intestine or in areas that are not
surgically resectable, such as the hip or thorax.
Because of the limited efficacy of these traditional therapies, there has been an interest in the
development of a product to direct and amplify the patient’s own immunologic response to the
organism. One attempt to achieve this has resulted in the development of the previously described IP.
Unfortunately, valid assessment of this product is complicated due to the paucity of knowledge
regarding the immune response against P. insidiosum, either with or without administration of the IP.
While serum concentrations of anti-P. insidiosum IgG have been measured after administration of
this product in naturally-infected dogs, these measurements have not been performed at any consistent
time (or in any consistent manner) after administration of the product. For this reason, it is unknown
whether administration of this immunotherapy product (IP) can be expected to interfere with serologicbased monitoring techniques. Adoption of this technology has been avoided by many veterinary
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clinicians because of concerns that it might interfere with serologic monitoring using IgG concentrations
with an ELISA.
1.1.G

Objectives

The specific objectives of this study are to characterize the IgG antibody responses of healthy dogs
treated with a purified protein mixture made from Pythium insidiosum, using the manufacturer’s
suggested protocol, and evaluate IP site reactions. An additional goal was to obtain serum samples for
future analysis of cytokine and other antibody isotype levels in serum. We hypothesize that repeated
administration of this commercially available immunotherapeutic product will increase IgG
concentrations over time following each administration of the IP in a population of healthy dogs. We do
not expect significant injection site reactions in the dogs in this study.
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Chapter 2. Quantitation of Anti-Pythium insidiosum Antibodies before and after Immunotherapy
in Healthy Dogs
2.1 Introduction
Pythium insidiosum is an aquatic oomycete that causes invasive, progressive granulomatous lesions
of the skin in dogs, horses, and cats, and of the gastrointestinal tract in dogs. Although pythiosis has
traditionally been observed most often in tropical and subtropical climates, over the past two decades it
has been recognized in a broader area, including California [1] and Wisconsin [2] in the United States.
Obtaining a definitive diagnosis may be challenging, as histologic findings are insufficiently unique to
differentiate pythiosis from lagenidiosis, paralagenidiosis, and zygomycosis. Methods that have been
used to confirm a diagnosis include IgG antibody serology [3] and culture followed by molecular
confirmation of isolate identity by species-specific PCR or ribosomal RNA gene sequencing [4]. In
addition to being used as a tool for initial diagnosis, IgG antibody serology has also been used to monitor
response to treatment in dogs, with maintenance of high antibody concentrations post-surgery
suggesting incomplete excision or early relapse [5]. Conversely, decreasing anti-P. insidiosum IgG
concentrations have been observed in patients that are cured [6].
The most effective treatment for pythiosis is wide surgical excision, which is sometimes followed by
antifungal chemotherapy. Unfortunately, complete surgical resection is often not possible because of
lesion location, and the effectiveness of medical therapy alone is limited by the fact that ergosterol is
not a major component of the oomycete cell membrane. As a result, alternative modes of therapy have
been explored, including an immunotherapy product (IP) that was originally developed for and
evaluated in horses, and which has subsequently been recommended for use in dogs and people.
Although there is published evidence showing some efficacy in horses, [7, 8] efficacy in dogs has not
been well evaluated and anecdotally appears to be poor [9]. In addition, although a mechanism of
action for the product has been proposed, [10] there have been no studies designed to evaluate the
effect of the IP on the immune response in any species.
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In addition to a lack of information about the mechanism of action of the IP, information regarding
its potential effect on post-treatment monitoring of anti-P. insidiosum IgG concentrations is limited. As
a result, some clinicians avoid use of immunotherapy because of concerns that it may interfere with
subsequent serologic monitoring. Although four individual canine cases have been described in which
anti-P. insidiosum IgG concentrations were monitored following treatment that included
immunotherapy, administration protocols (frequency, number, route) and post-IP administration
sampling intervals varied widely [2, 6, 11, 12].
Therefore, the goals of this study were to evaluate the effect of IP administration on anti-P.
insidiosum IgG concentrations in healthy dogs in order to better characterize the effect of IP
administration on the canine humoral immune response and to provide initial information about the
potential effect of IP administration on post-treatment serologic monitoring.
2.2 Materials and methods
Seven adult, female, purpose bred, intact hound-mixes from the Division of Laboratory Animal
Medicine (DLAM) colony were enrolled in this study with a median of 7 +/- 2.73 years. Dogs were
housed in either single or paired indoor AALAC-International-approved kennels, with controlled
temperature and climate for the duration of the study. Temperature and relative humidity (RH) were
measured using Onset Computer Corporation HOBO (Bourne, MA). Prior to the beginning of the study,
all dogs were screened for preexisting health conditions by a thorough physical examination, complete
blood count (CBC), biochemistry profile and urinalysis. All procedures described in this experiment were
approved by the Institutional Animal Care and Use Committee of Louisiana State University School of
Veterinary Medicine.
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The IP was obtained from Pan American Veterinary Laboratories (Hutto, TX) and was kept
refrigerated at 4° C until use. On days zero, seven and 21, the IP was administered as per
manufacturer’s instructions (1 mL subcutaneously; Figure one). Injection sites were rotated so as to not
inject in the same site more than once (cranial left thorax, cranial right thorax and caudal left thorax).
All administration sites were shaved and photographed pre- and post-injection to facilitate examination.
Injection sites were monitored for pruritus, swelling, induration, erythema, erosion, ulceration, necrosis
and discomfort. Body temperature was measured twice daily for seven days after every injection. A
temperature of 103.5° F or above was considered to be elevated [13]. Full physical examinations were
performed weekly for the duration of the study.

Figure 2.1. Timeline for the quantitation of anti-Pythium insidiosum IgG concentrations before and after
immunotherapy in healthy dogs. Serum was collected every seven days until Day 56 and three
injections of the immunotherapy product (IP) were administered on Day zero, seven and 21. Injection
sites were evaluated after each IP and temperature was collected twice daily for seven days postinjection.
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Blood collection (20 mL) via jugular or saphenous venipuncture was performed weekly (D0 until
D56; Figure one). Serum was harvested and stored in 200 µL aliquots at -80° C until analyzed. An ELISA
previously described for the serodiagnosis of pythiosis in dogs was used to measure anti-P. insidiosum
IgG concentrations [3]. Briefly, 96-well microtiter plates (Immulon 2HB, Thermo Scientific, Rochester,
NY) were coated overnight with a soluble mycelial antigen solution prepared from vortexed P.
insidiosum cultures. Wells were washed with phosphate-buffered saline-0.05% Tween (PBST), and then
blocked with bovine serum albumin in PBST (BSA-PBST). Sera were diluted in PBST (1:2000) and plated
in quadruplicate wells. Bound anti-P. insidiosum IgG was detected using a horseradish peroxidaseconjugated anti-canine IgG (Rockland Antibodies and Assays, Limerick, PA) in BSA-PBST, followed by the
addition of TMB two-component substrate (SeraCare, Milford, MA). Absorbance was measured at 450
nm using a BioTek Plate Reader (Epoch Microplate Spectrophotometer, Winooski, VT). Results were
recorded as percent positivity (PP) relative to a strong positive control serum run in quadruplicate on
each plate, calculated as:

𝑀𝑒𝑑𝑖𝑎𝑛 𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑒𝑟𝑢𝑚
𝑀𝑒𝑑𝑖𝑎𝑛 𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑠𝑒𝑟𝑢𝑚

𝑥 100% . A negative control of BSA-PBST

was included on each plate.
Anti-P. insidiosum IgG concentrations were evaluated over time in comparison to baseline. Data
was checked for normality using a Kolmogorov-Smirnoff Test, and was analyzed using a Repeated
Measures Analysis of Variance (ANOVA) as a Randomized Block Design (RBD) on the plates. Animal ID
was a random effect using Proc Mixed Procedure. Significance was set at P ≤0.05. SAS Version 9.4 (SAS
Institute Inc) was used for data analysis.
2.3 Results
Clinically significant adverse effects of the IP (including injection site induration, swelling and
pruritus) were not observed. Body temperature remained normal in all dogs at all time points.
Erythema was noted at 7/21 injection sites, but resolved within seven days of IP administration in all
instances. No dog developed erythema at all three injection sites. Mild crusting was noted in three
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dogs at either the first or the second injection site on Days 35 to 42, but these lesions resolved by Day
56 without treatment. These animals also had mild erythema associated with either site one (cranial left
thorax) or site two (cranial right thorax) during the study. By day 56, injection sites were normal in all
dogs.
Anti-P. insidiosum IgG concentrations remained within the previously-described reference interval
during all time points of this study (Table 1, Figure 2), and no significant change in PP was observed over
time (p = 0.2814; Figure 3, Table 1).
Overall, the PP demonstrated by the dogs was highly variable, and significant differences were
observed between all of the dogs at all time-points (including at baseline; Figure 2). One of the seven
dogs started with considerably higher baseline anti-P. insidiosum concentrations relative to the other six
dogs (Dog D, Figure 2, Baseline PP = 13.35%) and remained at this level throughout the study. When this
individual was removed from the model, the overall increase in PP was still not significant (p = 0.1157,
Table 1).
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Figure 2.2 Anti-P. insidiosum IgG concentrations reported as percent positivity (PP) in individual dogs
before and after immunotherapy.
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Figure 2.3: Median, quartiles and ranges of IgG PP (percent positivity) across time for anti-Pythium
insidiosum antibodies before and after immunotherapy product (IP).

Table 1: Averages, standard deviation and standard error for IgG PP (percent positivity) across time for
anti-P. insidiosum antibodies before and after immunotherapy product.

Days
0
7
14
21
28
35
42
49
56

Anti-P. insidiosum PP Data
p > 0.2814
Mean
Standard
Standard
Deviation
Error
7.457
3.023
1.142
7.374
0.889
0.336
8.911
1.995
0.754
8.514
1.272
0.480
8.797
1.601
0.605
9.234
2.525
0.954
9.177
2.152
0.813
8.448
1.552
0.586
8.32
0.955
0.361
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Mean
3.874
2.866
3.887
3.422
3.667
4.238
4.047
3.529
3.212

PP Data Excluding Dog 4
p > 0.1157
Standard
Standard
Deviation
Error
3.241
1.871
3.913
2.259
4.395
2.537
4.427
2.556
4.469
2.580
4.397
2.538
4.492
2.593
4.287
2.475
4.433
2.559

2.4 Discussion
Immunotherapy in the form of various P. insidiosum antigen extracts has been used for almost 40
years for the treatment of horses with pythiosis [14]. More recently, a commercially-available product
has been marketed for the treatment of P. insidiosum infections in horses and dogs. This product is a
combination of P. insidiosum hyphal and secreted antigens. There are several manuscripts suggesting
that this immunotherapy has some efficacy against P. insidiosum infections in horses and humans [7].
The response to immunotherapy has been studied most thoroughly in the horse. In 2003, Mendoza
reported resolution of pythiosis in 13 out of 18 horses using the IP evaluated in the current study [8].
These horses had previously failed to respond to topical medications or by surgical excision. A second
manuscript by Mendoza claimed that approximately 60% of 600 horses had been successfully treated by
immunotherapy, but specific details were not provided [10].
Immunotherapy has also been used with some success in humans. Administration of
immunotherapy was associated with clinical cure in one 14-year old boy with vascular pythiosis who had
previously failed to respond to antifungal or surgical therapy [15]. A subsequent case series
demonstrated that four out of eight humans treated with the IP were “without clinical or radiographic
signs of disease, i.e. arterial occlusion for about 24-30 months of follow-up” [16], while two patients
showed a partial response. All of these patients had previously failed to respond to medical and/or
surgical therapy. A later case series report described treatment success rates of 55.5% and 44.4% for
vascular and ocular pythiosis, respectively [17]. However, these patients also received systemic
(itraconazole and terbinafine, +/- voriconazole, ketoconazole or posaconazole) antifungal therapy.
Furthermore, all of the vascular pythiosis cases had also been treated by radical surgical excision, with
clinical cure observed only in patients in which clean surgical margins had been obtained.
In contrast, while there have been a small number of manuscripts demonstrating a good clinical
outcome in canine patients receiving the IP (in conjunction with other therapy), anecdotally the clinical
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efficacy of this product in this species appears to be poor [2, 6, 8, 11, 12, 18]. Of the 12 published
reports in which immunotherapy was used for the treatment of canine pythiosis, only five had a
favorable outcome. In one case series by Mendoza, immunotherapy alone was used to treat six dogs
which had previously failed to respond to surgery or antibiotic or antifungal therapy [8]. Two of these
dogs (one with intestinal involvement and one with cutaneous involvement) demonstrated clinical
resolution of the disease. Clinical resolution was also reported in one mixed breed dog with intestinal
pythiosis (which had also been treated by subtotal colectomy as well as a combination of itraconazole
and terbinafine); in one beagle with intestinal pythiosis (which had also received a combination of
itraconazole and terbinafine) and one dog with cutaneous pythiosis [6, 11, 12]. The remaining cases (all
with cutaneous disease) failed to demonstrate clinical improvement following immunotherapy
administration [2, 18].
The development of an effective immunotherapeutic product should ideally be based upon a
thorough understanding of the immunologic response to the organism in question. Although it is
beyond the scope of this manuscript to provide a detailed summary of the current knowledge of
antifungal immunity, it is possible to include a brief discussion of some of the key features. Effective
antifungal immunity is dependent upon a complex interaction between cells and elements of the innate
and adaptive immune systems. For most fungi, the development of a Th1 immune response appears to
be the most critical for effective elimination of the pathogen [19-21]. These responses are characterized
by a robust cell-mediated response, in which phagocytes (especially macrophages) become strongly
activated, increasing their rate of phagocytosis and their ability to kill phagocytized organisms [19, 21].
Other cells may also participate in the cell mediated response, including natural killer cells, which may
induce apoptosis and elimination of infected cells, and which may possibly be able to directly damage
extracellular fungi [22]. Th17 immune responses may also play a role in antifungal defense. These are
characterized by the recruitment and activation of neutrophils, which can both phagocytize and kill
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small fungal elements directly as well as damage or inhibit larger fungal elements via the elaboration of
neutrophil extracellular traps [21, 22]. While the critical role of Th1 and Th17 effector elements is well
established for most fungal infections, the relevance of Th2-mediated anti-fungal antibody responses
appears to be more variable and less certain. Although antibodies do appear to play a significant role in
the defense against certain organisms (namely Aspergillus), their role in effective defense against other
organisms (such as Candida) is less certain and may even be counterproductive [19].
In contrast to many true fungal pathogens (such as Candida and Aspergillus), there is a paucity
of knowledge regarding the immunologic processes associated with either the development of pythiosis
or with its resolution. In dogs and horses, infection with P. insidiosum has been associated with
development of anti-P. insidiosum IgG antibodies, and resolution of infection is typically associated with
a decrease in antibody concentrations [3, 23, 24]. However, it is unknown what role (if any) these
antibodies play in clearance of infection.
Clinical pythiosis is frequently referred to as a Th2 “polarized” immune response, while
successful treatment of P. insidiosum infections is commonly attributed to a Th1 immune response.
Although these statements are frequently repeated in the literature, there are no published data
regarding the response of immune cells or secreted factors to infection with P. insidiosum, and it may or
may not be valid to extend assumptions based upon knowledge of antifungal immune responses to this
non-fungal organism. Evidence cited in support of this assertion includes the observation that histologic
lesions induced by P. insidiosum are generally characterized by eosinophilic inflammation, while
resolving lesions typically contain fewer eosinophils and larger numbers of macrophages and
lymphocytes. There is a single published report of a human patient demonstrating a relative decrease in
serum P. insidiosum-specific IgE as well as interleukins 4 (IL-4) and IL-5, and a relative increase in IL-2
after successful therapy [16]. However, no similar studies have been performed in non-human species.
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While it is true that these observations might be consistent with a switch from a Th2 to a Th1-polarized
immune response, this evidence is far from definitive.
In the current study, administration of the IP to healthy dogs was not associated with a significant
change in anti-P. insidiosum IgG concentrations. One potential explanation is that the IP may simply fails
to induce a productive, effective immune response in this species. This idea would be supported by
clinical observations that the IP is fairly ineffective for the treatment of pythiosis in dogs. Given the
relatively higher clinical response rate to the IP in horses and humans in comparison to dogs it would be
interesting to determine whether there are significant IgG responses to IP administration in these
species. Another, perhaps more likely, explanation would be that the IP generates a predominantly cellmediated rather than humoral response.
The current work does have some limitations. The first involves the relatively small sample size. In
general, anti-P. insidiosum IgG concentrations (both pre- and post-IP administration) demonstrated
significant variability between individuals, although still remaining within the reference interval for
healthy dogs.
Perhaps a more significant limitation was that this study was performed on healthy dogs with no
known exposure to P. insidiosum. While this selection was necessary to determine the expected
antibody response to the IP under controlled conditions, our results might not necessarily reflect the
results seen in naturally infected dogs. It is possible that natural infection would produce enough
immunologic “priming” that subsequent challenge with the IP would be associated with a significant rise
in anti-P. insidiosum IgG concentrations. Further investigation would require administration of the IP to
infected animals. However, under these circumstances, it may be difficult to determine the relative
impact of the IP versus that of the infection itself.
In conclusion, this study demonstrated that administration of a commercially-available P. insidiosum
immunotherapeutic product does not produce a significant increase in anti-P. insidiosum IgG
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concentrations when administered to healthy dogs using the protocol suggested by the manufacturers.
These results may suggest a failure of the product to induce a productive immune response in this
species, or might indicate that factors other than IgG are responsible for the resolution of P. insidiosum
infections in the dog. Regardless, the lack of impact on serum anti-P. insidiosum IgG levels suggests that
administration of the IP would not be expected to interfere with subsequent serologic monitoring in
affected dogs. However, further evaluation of the antibody responses to this product in naturally
affected dogs will be required before a firm conclusion can be prudently drawn.
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Chapter 3. Conclusions
Pythium insidiosum is an aquatic oomycete found in tropical, subtropical and some temperate
climates worldwide, especially in the Gulf Coast States [1]. Pythiosis is characterized by severe,
progressive cutaneous or gastrointestinal disease [1] in dogs, horses and sometimes humans.
Treatment for this infection typically consists of surgical intervention combined with prolonged
antifungal treatment. Unfortunately, traditional antifungal medications have limited efficacy due to the
lack of ergosterol and chitin in P. insidiosum’s cellular wall, as the organism is more closely related to
algae than to fungi.
Recently, and immunotherapeutic product (IP) has been developed for use in horses, dogs and
humans. The IP evaluated in this study is a modification of Miller’s immunotherapy [2] and contains
both cytoplasmic antigens and secreted exoantigens from P. insidiosum [3]. Although this product
appears to be efficacious in horses and in some humans, anecdotally the response in dogs has been
poor. Evaluation of the efficacy of this product has been limited by several factors, including a lack of
information regarding its mechanism of action. In addition, many veterinarians have been hesitant to
use this product, as it is unknown whether administration of the IP affects anti-P. insidiosum IgG
antibody concentrations, which are commonly used to monitor the efficacy of treatment [4].
In this study, administration of the IP did not induce significant changes in anti-P. insidiosum IgG
antibody concentrations, nor were significant injection site reactions observed in the dogs used in this
study. The lack of a response in IgG antibody concentrations might suggest that administration of this
product does not induce the development of a productive immune response in the dog. Alternately, the
product might be more effective at producing a cell-mediated response rather than a humoral response.
Investigation of this hypothesis might include the determination of whether an IgG response is
generated after administration of this product to horses, in which the clinical response to this product is
better documented.
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Future studies include the characterization of the IgG antibody responses in healthy horses as well
as determination of the responses of other antibody isotypes such as IgE. Another area of future
research would include determination of serum cytokine profiles after administration of this product, as
well as in naturally infected animals at different stages of infection. There is a single report of a human
patient demonstrating a relative decrease in anti-P. insidiosum serum IgE concentrations as well as IL-4
and IL-5, and a relative increase in IL-2 after successful therapy [5].
In conclusion, this study demonstrated that administration of a commercially-available P. insidiosum
immunotherapy product does not produce a significant increase in anti-P. insidiosum IgG concentrations
when administered to healthy dogs using the protocol suggested by the manufacturers. These results
suggest that administration of the IP would not interfere with subsequent serological monitoring in
affected dogs. However, further evaluation of the antibody responses to this product in naturally
infected dogs will be required before a firm conclusion can be prudently drawn.
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